Patients' characteristics were stratified according to platelet count, PLR, and IL-6 tissutal expression then compared using Pearson's correlation. Significant correlations were observed between negative cervical cancer-related prognostic factors (advanced stage of disease, tumor size, high grading, positive LVSI, lymph nodes and parametrial involvement) and pro-inflammatory patient's status.

Conclusion Nowadays causal relationship between inflammation, innate immunity and cancer is more widely accepted; however, many of the molecular and cellular mechanisms mediating this relationship remain unresolved.

Ongoing inflammatory response was associated with poor outcomes in cervical cancer patients. A higher pre-treatment platelet count and PLR value associated with higher IL-6 tumoral expression could be used to predict poor prognosis in cervical cancer patients. Further investigations about inflammatory markers in prognostic models could contribute in early cervical patients' stratification and consequent management.

Disclosures None.

592

SENTINEL LYMPH NODE MAPPING IN EARLY-STAGE CERVICAL CANCER USING NEAR-INFRARED FLUORESCENCE IMAGING: A PROSPECTIVE PILOT STUDY

¹Anastasios Tranoulis, ²Hebatallah Awad, ²Christina Thompson, ²Amy Fisher, ²Jeremy Twigg. ¹The Pan-Birmingham Gynaecological Oncology Centre, Sandwell and West Birmingham NHS Trust, Birmingham; ²Jame's Cook University Hospital, Middlesbrough

10.1136/ijgc-2020-ESGO.204

Introduction/Background The aim of this pilot study was to ascertain the feasibility of sentinel lymph node (SLN) mapping in early-stage cervical cancer (CC) and evaluate factors affecting bilateral SLN detection.

Methodology This was a prospective cohort study spanning the period from January 2015 to March 2019. Women with early-stage CC (FIGO 2018 stage IA2 to IB2) scheduled to undergo robot-assisted laparoscopic radical hysterectomy or trachelectomy and SLN mapping with the Da Vinci Si Surgical System with near-infrared (NIR) imaging and indocyanine (ICG) fluorescence detection were enrolled. All patients were given the choice of complete pelvic lymph node dissection and SLN mapping or SLN mapping only. Cervical injection with ICG (2 ml) was performed for all women. Side-specific lymphadenectomy was performed when mapping was unsuccessful. The detection rate was calculated. Plausible correlations amongst the variables were examined using the Spearman's correlation coefficient (rho) and multivariate logistic regression.

Results The study enrolled 47 women [mean age 41.83 (24–69) years; mean body mass index (BMI) 29.02 (19–48) Kg/m²], of whom 43 underwent robot-assisted laparoscopic radical hysterectomy, whilst four radical trachelectomy. 31 (65.95%) women were diagnosed with squamous cell carcinoma, while 13 (27.69%) with adenocarcinoma, 2 (4.25%) with adeno-squamous cell carcinoma and 1 (2.11%) with endometrioid carcinoma, respectively. In total, 76 SLNs were removed. SLNs were most commonly identified in the external iliac basins (68.4%), followed by the obturator fossa (21.05%), internal iliac basins (6.6%) and common iliac basins (3.95%), respectively. SLN detection rates were

87.23% per patient, 84.05% per heme-pelvis and 68.09% bilaterally. Lymph node metastasis was detected in 3 women (6.3%). There was no statistical correlation between bilateral SLN detection and age (rho=-0.09, p=0.63), BMI (rho=-0.08, 0.57), adenocarcinoma or adeno-squamous histological sub-type (rho=0.14, p=0.35), grade 3 (rho=-0.09, p=0.55) or tumour size > 2 cm (rho=0.19, p=0.21). None of these covariates were significant in multivariate analysis.

Conclusion Intra-operative SLN mapping using fluorescence imaging with ICG is feasible, yields high diagnostic accuracy and it can be considered as an alternative to complete lymphadenectomy for carefully selected patients with early-stage CC.

Disclosures We certify that no party has a direct interest in the results of the research and that no benefit will be conferred to us or any organisation with which we are associated.

595

ASSESSING TRENDS IN STAGE AND OUTCOMES OF UTERINE CERVIX CANCER IN AN OPPORTUNISTIC SCREENING SETTING

¹Priscila Tavares Cruz Lugarinho, ¹Silvana Maria Quintana, ¹Jurandyr Moreira de Andrade, ¹Daniel Guimarães Tiezzi, ²Francisco Jose Candido Dos Reis. ¹Ribeirão Preto Medical School/ University of São Paulo; ²Ribeirão Preto Medical School/ Gynecology and Obstetrics

10.1136/ijgc-2020-ESGO.205

Introduction/Background Organized screening programs reduce cervical cancer incidence and mortality. However, in many low-middle income countries, the screening programs are opportunistic. In this work, we investigated the trends in cervical cancer mortality, advanced-stage at diagnosis, and screening coverage in an opportunistic setting.

Methodology In this large retrospective cohort, we analyzed data on invasive cervical cancer diagnosed between January 2000 and December 2014. Cancer data were provided by Fundação Oncocentro de São Paulo (FOSP) and screening coverage by the Instituto Brasileiro de Geografia e Estatística (IBGE). Five-year cervical mortality was calculated using the Fine and Gray regression model. Joinpoint regression analysis was used to estimate annual percentage changes (APC) for five-year mortality, the proportion of advanced stage, and screening coverage.

Results From 18,206 cases, we identified 6,479 deaths in five years of follow up due to cervical cancer. The leading risk factor was the advanced stage (sHR = 6.48, 95% CI 5.75 to 7.30). The rate of cervical cancer mortality was stable from 2000 to 2014 (APC=-0.106; 95%CI -0.730 to 0.522; P=0.720). The estimated proportion of women screened (in the last three years) was 81% in 2003, 83% in 2008, and 85% in 2013 (APC=0.443; 95%CI -4.913 to 6.102; P=0.492). The proportion of advanced stage reduced from 77% in 2000 to 71% in 2006 (APC=-1.294; 95%CI -2.322 to -0.256; P=0.020) and increased to 76% in 2014 (APC=0.924; 95%CI 0.248 to 1.605; P=0.012).

Conclusion Opportunistic screening strategies fail to achieve a similar proportion of early-stage diagnosis and reduced mortality in invasive uterine cervix cancer compared to organized screening programs.

Disclosures The authors have no conflict of interest to disclose.